Status:
COMPLETED
Clinical Evaluation of QFlu Combo Test
Lead Sponsor:
Cellex, Inc.
Collaborating Sponsors:
National Institute of Allergy and Infectious Diseases (NIAID)
Conditions:
Cough
Myalgia
Eligibility:
All Genders
Brief Summary
Currently effective antivials for influenza treatment are two influenza viral neuraminidase inhibitors, oseltamivir (Tamiflu) and zanamivir (Relenza). Resistance to these drugs is reflected by reduced...
Detailed Description
The study design is to collect samples from participants. A portion of the sample is used for drug resistance detection using the test (QFlu Combo Test) under investigation. The remaining portion of t...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Those who exhibit flu-like symptom(s) during a flu season and who (or whose guardians) are willing to participate in the study.
Exclusion
Key Trial Info
Start Date :
November 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 31 2012
Estimated Enrollment :
506 Patients enrolled
Trial Details
Trial ID
NCT01506583
Start Date
November 1 2010
End Date
May 31 2012
Last Update
August 6 2021
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35294
2
Northwestern University Feinberg School of Medicine
Chicago, Illinois, United States, 61611
3
University of Maryland School of Medicine
Baltimore, Maryland, United States, 21201